Figure 4.

CCG-203971 (CCG) reduces lung fibrosis after intratracheal bleomycin (bleo). Wild-type C57BL/6 mice were treated with 1.2 U/kg intratracheal bleomycin or phosphate-buffered saline (PBS) as previously described.³⁰ Starting on day 11 after bleomycin administration, the mice received CCG-203971 (100 mg/kg b.i.d. via i.p. injection) or an equal volume of vehicle control (dimethyl sulfoxide; DMSO). A: Weight changes over time. Weights were obtained on days 4, 6, and 8 before the administration of CCG-203971 and then daily through day 20 after the initiation of CCG-203971 administration. B: Hydroxyproline concentrations of both lungs at day 21 after bleomycin administration. Two independent experiments were completed with similar results, and the figure shown represents one of the experimental replicates. C: Representative histological examination. D: Representative picrosirius red staining. Data are expressed as means ± SEM. n = 7 mice per group (A and B). ^∗P < 0.05, ^∗∗P < 0.01, bleomycin/CCG-203971 and bleomycin/DMSO versus PBS/CCG-203971 and PBS/DMSO; ^††P < 0.01, PBS/CCG-203971 and PBS/DMSO versus bleomycin/DMSO; ^‡P < 0.05, bleomycin/CCG-203971 versus bleomycin/DMSO; ^§§§§P < 0.0001 versus untreated controls and CCG-203971 alone; ^¶¶¶¶P < 0.0001 versus bleomycin-treated mice.